Peptide Knowledge Base · Recovery
KPV: what it is, what the evidence says, and its real status
A small peptide people ask about for gut and inflammatory support.
Short version: an α-MSH fragment people ask about for gut and inflammation, often alongside BPC-157. Under FDA review, a waitlist, honestly labeled.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: Under PCAC review · PCAC · Jul 23–24, 2026.
Not available to prescribe today. Under PCAC review like the rest of the catalyst set; we keep it as a waitlist and education entry, never a product.
How does KPV work?
A tripeptide fragment of α-MSH proposed to modulate inflammatory signaling.
What it does — and what it does not do
What it does: Studied for gut and inflammatory support, often discussed with BPC-157.
What it does not do: It is not a treatment for any diagnosed gut condition, and it is not available to prescribe today.
How honest is the evidence?
Evidence grade D — preclinical or animal-dominant; no controlled human efficacy data. Read our grading methodology for what each grade means.
What we still don't know: Human evidence is sparse; effect on specific conditions is unproven.
WADA status: Not prohibited.
How it is taken
No established human clinical dosing; research-stage.
Who should not take it
Not characterized in humans; not a substitute for diagnosis or care of any gut condition.
Sources
α-MSH / KPV anti-inflammatory preclinical literature · FDA PCAC docket, Jul 2026
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.